A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Clinical trial NCT06099782 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06099782
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-26
- Primary completion
- 2025-04-09
- Enrollment
- 147
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.